<DOC>
	<DOCNO>NCT01283581</DOCNO>
	<brief_summary>The purpose study compare clinical response measurement technique several objective measure clinical efficacy use future ABSSSI ( Acute Bacterial Skin Skin Structure Infections ) clinical trial</brief_summary>
	<brief_title>A Study Assess Objective Endpoint Measurements Response Bacterial Skin Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Adult ( ≥ 18 year age ) men woman Sexually active woman men partner childbearing potential must agree use acceptable form contraception determine investigator participation study 30 day final dose study drug Female partner male subject also use additional reliable method contraception study 30 day final dose study drug Subjects must diagnosis ABSSSI one follow 4 infection type : cellulitis/erysipelas , wound infection , major cutaneous abscess , burn infection Subjects must lymph node enlargement due present infection least one follow symptom systemic infection : fever ≥ 38°C , lymphangitis , WBC ( white blood cell ) count ≥ 15,000 cells/μL , elevate Creactive protein ( &gt; 5.0mg/L ) In opinion investigator , subject must require suitable candidate IV antibiotic therapy A medical history significant hypersensitivity allergic reaction quinolones , linezolid , vancomycin , vancomycin derivative Women pregnant lactate Any chronic underlying skin condition site infection may complicate assessment response Subjects follow : infection involve prosthetic material foreign body , infection associate human animal bite , osteomyelitis , decubitus ulcer , diabetic foot ulcer , septic arthritis , mediastinitis , necrotizing fasciitis , anaerobic cellulitis , synergistic necrotizing cellulitis , myositis , tendinitis , endocarditis , toxic shock syndrome , gangrene , burn cover ≥ 10 % body surface area , severely impaired arterial blood supply , current evidence deep vein thrombosis superficial thrombophlebitis Minor abscesses , unless present one ABSSSI type Any infection expect require antimicrobial agent addition study drug Receipt &gt; 24 hour systemic antibiotic therapy 14 day enrollment unless one follow document : subject receive single dose shortacting antibacterial drug 3 day clinical trial enrollment surgical prophylaxis recently complete treatment antibacterial drug infection ABSSSI drug antibacterial activity bacterial pathogen cause ABSSSI Receipt 1 dose potentially effective antibacterial agent treatment ABSSSI study prior enrollment Receipt chronic antiinflammatory therapy longer 14 day enrollment Severely compromise immune system Subjects take medicinal product inhibits monoamine oxidases A B within 2 week Screening Hypertension define systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥110 mmHg confirm recheck within 20 minute initial read Subjects pheochromocytoma , thyrotoxicosis and/or subject take follow type medication : sympathomimetic agent , vasopressive agent , dopaminergic agent , agent potential serotonergic interaction Subjects carcinoid syndrome and/or subject take following medication : serotonin reuptake inhibitor , tricyclic antidepressant , serotonin 5HT1 receptor agonist , meperidine , buspirone Known history liver disease History severe renal impairment Life expectancy &lt; 3 month Any underlying disease , opinion investigator , could interfere subject 's ability participate study Subjects previously randomize study receive dose investigational drug within 30 day randomization Subjects &gt; 140 kg body weight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>